Skip to content
2000
Volume 12, Issue 1
  • ISSN: 2215-0838
  • E-ISSN: 2215-0846
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Introduction

Alzheimer’s disease (AD)-related dementia and mild cognitive impairment (MCI) are often complicated by CKD. This study aims to identify a therapeutic agent that can improve cognitive function and alleviate chronic kidney disease (CKD) in patients. It also explores the effectiveness of the combination of Ryoukeijutsukanto and Ourengedokuto (RO-8), a Kampo medicine, for treating cognitive decline and renal function impairment in patients with co-morbid CKD.

Methods

In this retrospective single-center study, patients with AD who visited the clinic were selected. Cognitive function and kidney function of all participants in the control and treatment groups were assessed using Hasegawa’s Dementia Scale (HDS-R) and the estimated glomerular filtration rate (eGFR), respectively. Statistical analyses were performed to measure the differences in the HDS-R scores and eGFR values before and after the observation or treatment period.

Results

The Kampo medicine RO-8 improved cognitive function in 90.9% (70/77) of patients and cognitive decline in 3.9% (3/77) of patients with AD and MCI. At the same time, 38.7% (29/75) of the patients with AD and MCI who were treated had chronic kidney disease (CKD), 65.5% (19/29) of which exhibited an improvement in the eGFR.

Discussion

Despite being a single-center and retrospective study, the findings underscore the potential of mixed Kampo medicine in restoring both cognitive and kidney function in patients with AD or MCI and CKD.

Conclusion

RO-8 may exert beneficial effects on cognitive decline in patients with Alzheimer’s dementia and MCI through an anti-inflammatory pathway and can be further explored as an alternative anti-inflammatory drug to treat AD.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/ctm/10.2174/0122150838396773250720081201
2025-07-30
2025-09-27

  • From This Site

    /content/journals/ctm/10.2174/0122150838396773250720081201
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/ctm/12/1/CTM-12-E22150838396773.html?itemId=/content/journals/ctm/10.2174/0122150838396773250720081201&mimeType=html&fmt=ahah

References

  1. LiX. FengX. SunX. HouN. HanF. LiuY. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2019.Front. Aging Neurosci.20221493748610.3389/fnagi.2022.93748636299608
     [Google Scholar]
  2. NicholsE. SteinmetzJ.D. VollsetS.E. FukutakiK. ChalekJ. Abd-AllahF. AbdoliA. AbualhasanA. Abu-GharbiehE. AkramT.T. Al HamadH. AlahdabF. AlaneziF.M. AlipourV. AlmustanyirS. AmuH. AnsariI. ArablooJ. AshrafT. Astell-BurtT. AyanoG. Ayuso-MateosJ.L. BaigA.A. BarnettA. BarrowA. BauneB.T. BéjotY. BezabheW.M.M. BezabihY.M. BhagavathulaA.S. BhaskarS. BhattacharyyaK. BijaniA. BiswasA. BollaS.R. BoloorA. BrayneC. BrennerH. BurkartK. BurnsR.A. CámeraL.A. CaoC. CarvalhoF. Castro-de-AraujoL.F.S. Catalá-LópezF. CerinE. ChavanP.P. CherbuinN. ChuD-T. CostaV.M. CoutoR.A.S. DadrasO. DaiX. DandonaL. DandonaR. De la Cruz-GóngoraV. DhamnetiyaD. Dias da SilvaD. DiazD. DouiriA. EdvardssonD. EkholuenetaleM. El SayedI. El-JaafaryS.I. EskandariK. EskandariehS. EsmaeilnejadS. FaresJ. FaroA. FarooqueU. FeiginV.L. FengX. FereshtehnejadS-M. FernandesE. FerraraP. FilipI. FillitH. FischerF. GaidhaneS. GalluzzoL. GhashghaeeA. GhithN. GialluisiA. GilaniS.A. GlavanI-R. GnedovskayaE.V. GolechhaM. GuptaR. GuptaV.B. GuptaV.K. HaiderM.R. HallB.J. HamidiS. HanifA. HankeyG.J. HaqueS. HartonoR.K. HasaballahA.I. HasanM.T. HassanA. HayS.I. HayatK. HegazyM.I. HeidariG. Heidari-SoureshjaniR. HerteliuC. HousehM. HussainR. HwangB-F. IacovielloL. IavicoliI. IlesanmiO.S. IlicI.M. IlicM.D. IrvaniS.S.N. IsoH. IwagamiM. JabbarinejadR. JacobL. JainV. JayapalS.K. JayawardenaR. JhaR.P. JonasJ.B. JosephN. KalaniR. KandelA. KandelH. KarchA. KasaA.S. KassieG.M. KeshavarzP. KhanM.A.B. KhatibM.N. KhojaT.A.M. KhubchandaniJ. KimM.S. KimY.J. KisaA. KisaS. KivimäkiM. KoroshetzW.J. KoyanagiA. KumarG.A. KumarM. LakH.M. LeonardiM. LiB. LimS.S. LiuX. LiuY. LogroscinoG. LorkowskiS. LucchettiG. Lutzky SauteR. MagnaniF.G. MalikA.A. MassanoJ. MehndirattaM.M. MenezesR.G. MeretojaA. MohajerB. Mohamed IbrahimN. MohammadY. MohammedA. MokdadA.H. MondelloS. MoniM.A.A. MoniruzzamanM. MossieT.B. NagelG. NaveedM. NayakV.C. Neupane KandelS. NguyenT.H. OanceaB. OtstavnovN. OtstavnovS.S. OwolabiM.O. Panda-JonasS. Pashazadeh KanF. PasovicM. PatelU.K. PathakM. PeresM.F.P. PerianayagamA. PetersonC.B. PhillipsM.R. PinheiroM. PiradovM.A. PondC.D. PotashmanM.H. PottooF.H. PradaS.I. RadfarA. RaggiA. RahimF. RahmanM. RamP. RanasingheP. RawafD.L. RawafS. RezaeiN. RezapourA. RobinsonS.R. RomoliM. RoshandelG. SahathevanR. SahebkarA. SahraianM.A. SathianB. SattinD. SawhneyM. SaylanM. SchiavolinS. SeylaniA. ShaF. ShaikhM.A. ShajiK.S. ShannawazM. ShettyJ.K. ShigematsuM. ShinJ.I. ShiriR. SilvaD.A.S. SilvaJ.P. SilvaR. SinghJ.A. SkryabinV.Y. SkryabinaA.A. SmithA.E. SoshnikovS. SpurlockE.E. SteinD.J. SunJ. Tabarés-SeisdedosR. ThakurB. TimalsinaB. Tovani-PaloneM.R. TranB.X. TsegayeG.W. Valadan TahbazS. ValdezP.R. VenketasubramanianN. VlassovV. VuG.T. VuL.G. WangY-P. WimoA. WinklerA.S. YadavL. Yahyazadeh JabbariS.H. YamagishiK. YangL. YanoY. YonemotoN. YuC. YunusaI. ZadeyS. ZastrozhinM.S. ZastrozhinaA. ZhangZ-J. MurrayC.J.L. VosT. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019.Lancet Public Health202272e105e12510.1016/S2468‑2667(21)00249‑834998485
     [Google Scholar]
  3. BaiW. ChenP. CaiH. ZhangQ. SuZ. CheungT. JacksonT. ShaS. XiangY.T. Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: A meta-analysis and systematic review of epidemiology studies.Age Ageing2022518afac17310.1093/ageing/afac17335977150
     [Google Scholar]
  4. SinghB. DayC.M. AbdellaS. GargS. Alzheimer’s disease current therapies, novel drug delivery systems and future directions for better disease management.J. Control. Release202436740242410.1016/j.jconrel.2024.01.04738286338
     [Google Scholar]
  5. SinghY.P. PrasadS. KumarH. A comprehensive analysis on galantamine based hybrids for the management of Alzheimer’s disease.Chem. Biol. Drug Des.202410457000410.1111/cbdd.7000439494477
     [Google Scholar]
  6. SinghY.P. KumarH. A recent update on huprine and its hybrids as a potential multifunctional agent for the treatment of Alzheimer’s disease.Chem. Biol. Drug Des.202410321447810.1111/cbdd.14478
     [Google Scholar]
  7. GaurA. SinghY.P. SharmaR. BainsalN. Deoxyvasicinone hybrids in the management of Alzheimer’s disease: Recent advances on manmade derivatives, pharmacological activities, and structure–activity relationship.Arch. Pharm.20253581240074210.1002/ardp.20240074239731272
     [Google Scholar]
  8. LeiX. XuH. WangY. GaoH. ZhaoD. ZhangJ. ZhuZ. ZuoK. LiuY. LiX. ZhangN. Integrating network pharmacology and component analysis to study the potential mechanisms of qi-Fu-Yin decoction in treating Alzheimer’s disease.Drug Des. Devel. Ther.2023172841285810.2147/DDDT.S40262437727255
     [Google Scholar]
  9. ShangY. WangS. WeiC. GuoY. ZhaoH. GaoX. GaoZ. XieH. WangZ. Association of chronic kidney disease with cognitive impairment risk in middle-aged and older adults: The first longitudinal evidence from CHARLS.Sci. Rep.20241412326510.1038/s41598‑024‑74420‑639370425
     [Google Scholar]
  10. ViggianoD. WagnerC.A. MartinoG. NedergaardM. ZoccaliC. UnwinR. CapassoG. Mechanisms of cognitive dysfunction in CKD.Nat. Rev. Nephrol.202016845246910.1038/s41581‑020‑0266‑932235904
     [Google Scholar]
  11. IkedaY. FunamotoM. KishiS. ImanishiM. AiharaK. KashiwadaY. TsuchiyaK. The novel preventive effect of a Japanese ethical Kampo extract formulation TJ-90 (Seihaito) against cisplatin-induced nephrotoxicity.Phytomedicine202210315421310.1016/j.phymed.2022.15421335671634
     [Google Scholar]
  12. ShimizuM. TakayamaS. IshizawaK. AbeM. IshiiT. Kampo medicine can improve quality of life and prolong hemodialysis implementation in patients with advanced-stage chronic kidney disease.Tradit. Kampo Med.20218322923310.1002/tkm2.1291
     [Google Scholar]
  13. TakayamaS. TomitaN. AritaR. OnoR. KikuchiA. IshiiT. Kampo medicine for various aging-related symptoms: A review of geriatric syndrome.Front. Nutr.202078610.3389/fnut.2020.0008632766269
     [Google Scholar]
  14. OkamotoH. ChinoA. HirasakiY. UedaK. IyoM. NamikiT. Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: A case report and literature review of the evidence for use of these Kampo herbal formulae.Neuropsychiatr. Dis. Treat.2013915115510.2147/NDT.S3831823378767
     [Google Scholar]
  15. KuritaM. NishinoS. TeranishiM. TakeyoshiK. SatoT. OkuboY. TatenoA. OkuboY. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia, and pharmacological consideration.Int. J. Neuropsychopharmacol.202528Suppl. 1i207i20810.1093/ijnp/pyae059.362
     [Google Scholar]
  16. ShimoideY. An end to suffering from atopic dermatitis.J. Allergy Clin. Immunol.20091232S4110.1016/j.jaci.2008.12.1099
     [Google Scholar]
  17. ShimoideY. Overturning the conventional notion of bronchial asthma treatment.J. Allergy Clin. Immunol.20121292AB7210.1016/j.jaci.2011.12.594
     [Google Scholar]
  18. ShimoideY. A herbal medicine that normalizes hormonal abnormalities caused by hypothyroidism due to chronic thyroiditis.2017Available from: https://patentimages.storage.googleapis.com/18/7e/05/0a57daf79ef25c/JP6154566B1.pdf
  19. ShimoideY. Kampo medicine for improving cognitive function in Alzheimer’s dementia or mild cognitive impairment and treating at least one disease from the group consisting of overactive bladder, constipation, and chronic kidney diseases complicated by them with one drug.US Patent 10,660,929 B22018
  20. IwataY. MiyaoM. HirotsuA. TatsumiK. MatsuyamaT. UetsukiN. TanakaT. The inhibitory effects of Orengedokuto on inducible PGE2 production in BV-2 microglial cells.Heliyon2021780775910.1016/j.heliyon.2021.e0775934458607
     [Google Scholar]
  21. XieZ. TongS. ChuX. FengT. GengM. Chronic kidney disease and cognitive impairment: The kidney-brain axis.Kidney Dis.20228427528510.1159/00052447536157262
     [Google Scholar]
  22. ZhangC.Y. HeF.F. SuH. ZhangC. MengX.F. Association between chronic kidney disease and Alzheimer’s disease: An update.Metab. Brain Dis.202035688389410.1007/s11011‑020‑00561‑y32246323
     [Google Scholar]
  23. KatoS. Development of the revised version of Hasegawa’s Dementia Scale (HDS-R).Jpn. Geriatr. Psychiatr. Med.1991213391347
     [Google Scholar]
  24. Japanese Society of Nephrology [Special issue: Clinical practice guidebook for diagnosis and treatment of CKD].Nippon Jinzo Gakkai Shi200749775786118019594
     [Google Scholar]
  25. TombaughT.N. McIntyreN.J. The mini-mental state examination: A comprehensive review.J. Am. Geriatr. Soc.199240992293510.1111/j.1532‑5415.1992.tb01992.x1512391
     [Google Scholar]
  26. StevensP.E. LevinA. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline.Ann. Intern. Med.20131581182583010.7326/0003‑4819‑158‑11‑201306040‑0000723732715
     [Google Scholar]
  27. LiF. HarmerP. LiuY. ChouL.S. Tai Ji Quan and global cognitive function in older adults with cognitive impairment: A pilot study.Arch. Gerontol. Geriatr.201458343443910.1016/j.archger.2013.12.00324398166
     [Google Scholar]
  28. GuoC. ShaoW. LiF. TanX. XieY. Effectiveness of traditional chinese medicine (TCM) exercise therapy intervention on the cognitive function in the elderly: A systematic review and meta-analysis.Geriatr. Nurs.20245835236010.1016/j.gerinurse.2024.06.00138878735
     [Google Scholar]
  29. ZhangJ. ZhangY. WangJ. XiaY. ZhangJ. ChenL. Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies.Signal Transduct. Target. Ther.20249121110.1038/s41392‑024‑01911‑339174535
     [Google Scholar]
  30. SchneiderL. A resurrection of aducanumab for Alzheimer’s disease.Lancet Neurol.202019211111210.1016/S1474‑4422(19)30480‑631978357
     [Google Scholar]
  31. TampiR.R. ForesterB.P. AgroninM. Aducanumab: Evidence from clinical trial data and controversies.Drugs Context202110101910.7573/dic.2021‑7‑334650610
     [Google Scholar]
  32. EganM.F. KostJ. VossT. MukaiY. AisenP.S. CummingsJ.L. TariotP.N. VellasB. van DyckC.H. BoadaM. ZhangY. LiW. FurtekC. MahoneyE. Harper MozleyL. MoY. SurC. MichelsonD. Randomized trial of Verubecestat for prodromal Alzheimer’s disease.N. Engl. J. Med.2019380151408142010.1056/NEJMoa181284030970186
     [Google Scholar]
  33. LannfeltL. RelkinN.R. SiemersE.R. Amyloid-ß-directed immunotherapy for Alzheimer’s disease.J. Intern. Med.2014275328429510.1111/joim.1216824605809
     [Google Scholar]
  34. AckleyS.F. ZimmermanS.C. BrenowitzW.D. Tchetgen TchetgenE.J. GoldA.L. ManlyJ.J. MayedaE.R. FilshteinT.J. PowerM.C. ElahiF.M. BrickmanA.M. GlymourM.M. Effect of reductions in amyloid levels on cognitive change in randomized trials: Instrumental variable meta-analysis.BMJ2021372156n15610.1136/bmj.n15633632704
     [Google Scholar]
  35. JonssonT. StefanssonH. SteinbergS. JonsdottirI. JonssonP.V. SnaedalJ. BjornssonS. HuttenlocherJ. LeveyA.I. LahJ.J. RujescuD. HampelH. GieglingI. AndreassenO.A. EngedalK. UlsteinI. DjurovicS. Ibrahim-VerbaasC. HofmanA. IkramM.A. van DuijnC.M. ThorsteinsdottirU. KongA. StefanssonK. Variant of TREM2 associated with the risk of Alzheimer’s disease.N. Engl. J. Med.2013368210711610.1056/NEJMoa121110323150908
     [Google Scholar]
  36. MarslandA.L. GianarosP.J. AbramowitchS.M. ManuckS.B. HaririA.R. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults.Biol. Psychiatry200864648449010.1016/j.biopsych.2008.04.01618514163
     [Google Scholar]
  37. KlyucherevT.O. OlszewskiP. ShalimovaA.A. ChubarevV.N. TarasovV.V. AttwoodM.M. SyvänenS. SchiöthH.B. Advances in the development of new biomarkers for Alzheimer’s disease.Transl. Neurodegener.20221112510.1186/s40035‑022‑00296‑z35449079
     [Google Scholar]
  38. ThakurS. DhapolaR. SarmaP. MedhiB. ReddyD.H. Neuroinflammation in Alzheimer’s disease: Current progress in molecular signaling and therapeutics.Inflammation202346111710.1007/s10753‑022‑01721‑135986874
     [Google Scholar]
  39. DongY. YuH. LiX. BianK. ZhengY. DaiM. FengX. SunY. HeY. YuB. ZhangH. WuJ. YuX. WuH. KongW. Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer’s disease.J. Neuroinflammation202219120510.1186/s12974‑022‑02567‑y35971179
     [Google Scholar]
  40. RatherM.A. KhanA. AlshahraniS. RashidH. QadriM. RashidS. AlsaffarR.M. KamalM.A. RehmanM.U. Inflammation and Alzheimer’s disease: Mechanisms and therapeutic implications by natural products.Mediators Inflamm.2021202112110.1155/2021/998295434381308
     [Google Scholar]
  41. ChenH. LiuN. ZhuangS. Macrophages in renal injury, repair, fibrosis following acute kidney injury and targeted therapy.Front. Immunol.20221393429910.3389/fimmu.2022.93429935911736
     [Google Scholar]
  42. BireyF. KlocM. ChavaliM. HusseinI. WilsonM. ChristoffelD.J. ChenT. FrohmanM.A. RobinsonJ.K. RussoS.J. MaffeiA. AguirreA. Genetic and stress-induced loss of NG2 glia triggers emergence of depressive-like behaviors through reduced secretion of FGF2.Neuron201588594195610.1016/j.neuron.2015.10.04626606998
     [Google Scholar]
  43. NakanoM. TamuraY. YamatoM. KumeS. EguchiA. TakataK. WatanabeY. KataokaY. NG2 glial cells regulate neuroimmunological responses to maintain neuronal function and survival.Sci. Rep.2017714204110.1038/srep4204128195192
     [Google Scholar]
  44. MercadoG. KaeuferC. RichterF. PeelaertsW. Infections in the etiology of Parkinson’s disease and synucleinopathies: A renewed perspective, mechanistic insights, and therapeutic implications.J. Parkinsons Dis.20241471301132910.3233/JPD‑24019539331109
     [Google Scholar]
  45. ZhangW. XiaoD. MaoQ. XiaH. Role of neuroinflammation in neurodegeneration development.Signal Transduct. Target. Ther.20238126710.1038/s41392‑023‑01486‑537433768
     [Google Scholar]
  46. ChenS. SaeedA.F.U.H. LiuQ. JiangQ. XuH. XiaoG.G. RaoL. DuoY. Macrophages in immunoregulation and therapeutics.Signal Transduct. Target. Ther.20238120710.1038/s41392‑023‑01452‑137211559
     [Google Scholar]
  47. HolmquistS. NordströmA. NordströmP. The association of depression with subsequent dementia diagnosis: A Swedish nationwide cohort study from 1964 to 2016.PLoS Med.2020171100301610.1371/journal.pmed.100301631917808
     [Google Scholar]
/content/journals/ctm/10.2174/0122150838396773250720081201
Loading
New Kampo Improves Cognitive Decline in Alzheimer’s Disease and Mild Cognitive Impairment and Renal Function Decline in Chronic Kidney Disease
Current Traditional Medicine 12, E22150838396773 (2026); https://doi.org/10.2174/0122150838396773250720081201
/content/journals/ctm/10.2174/0122150838396773250720081201
/content/journals/ctm/10.2174/0122150838396773250720081201
Loading

Data & Media loading...

Supplements

Supplementary material is available on the Publisher’s website.

file format download Download

  • Article Type:     Research Article
Keyword(s): Alzheimer’s disease; anti-inflammation; CKD; dementia; Kampo medicine; MCI

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test